M H Davidson

Summary

Affiliation: Radiant Research
Country: USA

Publications

  1. pmc Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial
    Michael Davidson
    Radiant Research, Chicago, IL 60610, USA
    Cardiovasc Drugs Ther 26:349-58. 2012
  2. doi request reprint Niacin therapy: an evolving paradigm for the management of mixed dyslipidemia and low high-density lipoprotein cholesterol. Introduction
    Michael H Davidson
    University of Chicago, Pritzker School of Medicine, Chicago, Illinois 60637 5415, USA
    Am J Cardiol 101:1B-2B. 2008
  3. ncbi request reprint Overview of prevention and treatment of atherosclerosis with lipid-altering therapy for pharmacy directors
    Michael H Davidson
    Rush University Medical Center, 1725 West Harrison St, Ste 1159, Chicago, IL 60612, USA
    Am J Manag Care 13:S260-9. 2007
  4. ncbi request reprint High-density lipoprotein metabolism: potential therapeutic targets
    Michael H Davidson
    University of Chicago, Pritzker School of Medicine, Chicago, Illinois, USA
    Am J Cardiol 100:n32-40. 2007
  5. ncbi request reprint Targeting high-density lipoprotein cholesterol in the management of cardiovascular disease
    Michael H Davidson
    Pritzker School of Medicine, University of Chicago, Chicago, IL, USA
    Am Heart Hosp J 5:210-6. 2007
  6. ncbi request reprint The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review
    Michael H Davidson
    University of Chicago, Pritzker School of Medicine, Executive Medical Director, Radiant Research, Chicago, IL, USA
    Expert Opin Pharmacother 8:2569-78. 2007
  7. ncbi request reprint Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study
    Michael H Davidson
    Radiant Research, 515 North State Street, Suite 2700, Chicago, IL 60610, USA
    Clin Ther 29:1354-67. 2007
  8. ncbi request reprint Safety of aggressive lipid management
    Michael H Davidson
    Radiant Research, Rush University Medical Center, Chicago, Illinois, USA
    J Am Coll Cardiol 49:1753-62. 2007
  9. ncbi request reprint Safety considerations with fibrate therapy
    Michael H Davidson
    Rush University Medical Center, Chicago, Illinois, USA
    Am J Cardiol 99:3C-18C. 2007
  10. ncbi request reprint Global risk management in patients with type 2 diabetes mellitus
    Michael H Davidson
    Rush University Medical Center, Chicago, Illinois 60612, USA
    Am J Cardiol 99:41B-50B. 2007

Collaborators

Detail Information

Publications89

  1. pmc Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial
    Michael Davidson
    Radiant Research, Chicago, IL 60610, USA
    Cardiovasc Drugs Ther 26:349-58. 2012
    ....
  2. doi request reprint Niacin therapy: an evolving paradigm for the management of mixed dyslipidemia and low high-density lipoprotein cholesterol. Introduction
    Michael H Davidson
    University of Chicago, Pritzker School of Medicine, Chicago, Illinois 60637 5415, USA
    Am J Cardiol 101:1B-2B. 2008
  3. ncbi request reprint Overview of prevention and treatment of atherosclerosis with lipid-altering therapy for pharmacy directors
    Michael H Davidson
    Rush University Medical Center, 1725 West Harrison St, Ste 1159, Chicago, IL 60612, USA
    Am J Manag Care 13:S260-9. 2007
    ..Emphasis is on newer data regarding the effect of statins in retarding progression of atherosclerosis or even inducing regression of atherosclerosis...
  4. ncbi request reprint High-density lipoprotein metabolism: potential therapeutic targets
    Michael H Davidson
    University of Chicago, Pritzker School of Medicine, Chicago, Illinois, USA
    Am J Cardiol 100:n32-40. 2007
    ....
  5. ncbi request reprint Targeting high-density lipoprotein cholesterol in the management of cardiovascular disease
    Michael H Davidson
    Pritzker School of Medicine, University of Chicago, Chicago, IL, USA
    Am Heart Hosp J 5:210-6. 2007
    ..This article reviews the strategies for targeting HDL cholesterol to optimize outcomes in CHD...
  6. ncbi request reprint The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review
    Michael H Davidson
    University of Chicago, Pritzker School of Medicine, Executive Medical Director, Radiant Research, Chicago, IL, USA
    Expert Opin Pharmacother 8:2569-78. 2007
    ..This article reviews the clinical efficacy and use of colesevelam HCL for the management of dyslipidemia...
  7. ncbi request reprint Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study
    Michael H Davidson
    Radiant Research, 515 North State Street, Suite 2700, Chicago, IL 60610, USA
    Clin Ther 29:1354-67. 2007
    ..The National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) has identified non-HDL-C as a secondary therapeutic target in these patients, but treatment goals may not be reached with statin monotherapy alone...
  8. ncbi request reprint Safety of aggressive lipid management
    Michael H Davidson
    Radiant Research, Rush University Medical Center, Chicago, Illinois, USA
    J Am Coll Cardiol 49:1753-62. 2007
    ..In order to optimize patient outcomes, clinicians should be aware of specific patient characteristics, such as advancing age, gender, body mass index, or glomerular filtration rate, which predict muscle and hepatic statin toxicity...
  9. ncbi request reprint Safety considerations with fibrate therapy
    Michael H Davidson
    Rush University Medical Center, Chicago, Illinois, USA
    Am J Cardiol 99:3C-18C. 2007
    ....
  10. ncbi request reprint Global risk management in patients with type 2 diabetes mellitus
    Michael H Davidson
    Rush University Medical Center, Chicago, Illinois 60612, USA
    Am J Cardiol 99:41B-50B. 2007
    ..Global risk reduction with aggressive low-density lipoprotein reduction and through the additional normalization of glucose levels and blood pressure can help to reduce absolute risk in this very high-risk population...
  11. ncbi request reprint Squalene synthase inhibition: a novel target for the management of dyslipidemia
    Michael H Davidson
    Radiant Research, 515 N State Street, Suite 2700, Chicago, IL 60610, USA
    Curr Atheroscler Rep 9:78-80. 2007
    ..Human clinical trial data with TAK-475, a novel and potent inhibitor of squalene synthase, have not yet been published...
  12. ncbi request reprint Differences between clinical trial efficacy and real-world effectiveness
    Michael H Davidson
    Rush University Medical Center, 1725 W Harrison St, Ste 1159, Chicago, IL 60612, USA
    Am J Manag Care 12:S405-11. 2006
    ..This review sets forth compelling data that starting patients on or switching to high-efficacy LDL-C-lowering therapy enhances achievement of NCEP ATP III guidelines outside of the controlled trial setting...
  13. ncbi request reprint Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels
    Michael H Davidson
    Rush Presbyterian St Luke s Medical Center, Chicago, Illinois, USA
    J Am Coll Cardiol 48:1774-81. 2006
    ..This study was designed to evaluate the efficacy and safety of torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, in subjects with low high-density lipoprotein cholesterol (HDL-C) levels...
  14. ncbi request reprint Rosuvastatin in elderly patients
    Michael H Davidson
    Preventive Cardiology, The University of Chicago, Pritzker School of Medicine, Chicago, Illinois, USA
    Drugs Aging 24:933-44. 2007
    ..As yet, however, cardiovascular endpoint data for rosuvastatin are not available...
  15. ncbi request reprint Lipid-lowering effects of statins: a comparative review
    Michael H Davidson
    Radiant Research, Chicago, IL, USA
    Expert Opin Pharmacother 7:1701-14. 2006
    ....
  16. ncbi request reprint Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids
    Michael H Davidson
    Radiant Research and Rush University Medical Center, Chicago, Illinois, USA
    Am J Cardiol 98:27i-33i. 2006
    ..These combined effects support the use of omega-3 fatty acids as a valuable clinical tool for the treatment of hypertriglyceridemia...
  17. ncbi request reprint Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects
    Michael H Davidson
    Department of Cardiology, Rush University Medical College, 60610, USA
    Clin Cardiol 29:268-73. 2006
    ....
  18. doi request reprint A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia
    Michael H Davidson
    The University of Chicago Pritzker School of Medicine, 515 North State Street, Suite 2700, Chicago, IL 60654, USA
    J Clin Lipidol 5:76-81. 2011
    ..This review summarizes the clinical data regarding the efficacy and safety of bile acid sequestrants in this specialized population...
  19. doi request reprint Niacin use and cutaneous flushing: mechanisms and strategies for prevention
    Michael H Davidson
    University of Chicago, Pritzker School of Medicine, Chicago, Illinois 60610 4310, USA
    Am J Cardiol 101:14B-19B. 2008
    ..Because niacin has recognized cardiovascular benefits, promoting patient awareness of factors that can minimize niacin-induced flushing can help enhance the tolerability of this valuable dyslipidemic agent...
  20. doi request reprint Introduction. U.S. incidence of coronary artery disease
    Michael H Davidson
    Pritzker School of Medicine, University of Chicago, 515 North State Street, Chicago, IL 60610, USA
    Am J Cardiol 101:1F-2F. 2008
  21. doi request reprint Focusing on high-density lipoprotein for coronary heart disease risk reduction
    Michael H Davidson
    Department of Medicine, Section of Cardiology, Pritzker School of Medicine, University of Chicago, Chicago, IL 60637, USA
    Cardiol Clin 29:105-22. 2011
    ..This article presents a review of the biologic actions of HDL that can serve as a potential basis for antiatherosclerotic activity and discusses strategies for targeting HDL for CHD risk reduction...
  22. doi request reprint Therapies targeting exogenous cholesterol uptake: new insights and controversies
    Michael H Davidson
    Clinical Professor, Director of Preventive Cardiology, The University of Chicago Pritzker School of Medicine, 515 North State Street, Suite 2700, Chicago, IL 60654, USA
    Curr Atheroscler Rep 13:95-100. 2011
    ....
  23. doi request reprint Update on CETP inhibition
    Michael H Davidson
    The University of Chicago Pritzker School of Medicine, 515 North State Street, Suite 2700, Chicago, IL 60654, USA
    J Clin Lipidol 4:394-8. 2010
    ..CETP inhibition as a therapeutic strategy remains a valid option to be tested with a CETP inhibitor that does not share torcetrapib's off-target effects...
  24. doi request reprint A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia
    Michael H Davidson
    The University of Chicago Pritzker School of Medicine, Chicago, IL, USA
    Am J Cardiovasc Drugs 10:305-14. 2010
    ....
  25. doi request reprint Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study
    Michael H Davidson
    The University of Chicago, Pritzker School of Medicine, Chicago, Illinois, USA
    Clin Ther 31:2824-38. 2009
    ..Coadministration of statin and fenofibrate monotherapies is frequently used to treat patients with dyslipidemia; however, a fixed-dose combination (FDC) tablet is not currently marketed...
  26. doi request reprint Novel targets that affect high-density lipoprotein metabolism: the next frontier
    Michael H Davidson
    University of Chicago, Pritzker School of Medicine, Chicago, Illinois, USA
    Am J Cardiol 104:52E-7E. 2009
    ..This article reviews current options for the therapeutic management of HDL cholesterol, including discussion of novel agents aimed at reducing cardiovascular disease risk in patients with low levels of HDL cholesterol...
  27. ncbi request reprint An urgent matter-identifying your patients' cardiovascular risk and improving their outcomes. Assessing cardiovascular risk one patient at a time
    Michael H Davidson
    University of Chicago Pritzker, IL, USA
    J Fam Pract 58:S26-31. 2009
    ..Risk assessment strategies and new data about cardiovascular risk of interest to family physicians are presented here...
  28. doi request reprint Effects of consumption of pomegranate juice on carotid intima-media thickness in men and women at moderate risk for coronary heart disease
    Michael H Davidson
    Radiant Research and University of Chicago, Chicago, IL, USA
    Am J Cardiol 104:936-42. 2009
    ....
  29. doi request reprint Apolipoprotein measurements: is more widespread use clinically indicated?
    Michael H Davidson
    Preventive Cardiology Center, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
    Clin Cardiol 32:482-6. 2009
    ....
  30. doi request reprint A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome
    Michael Davidson
    Pritzker School of Medicine, University of Chicago, Chicago, Illinois 60610, USA
    Am J Cardiol 102:19L-27L. 2008
    ..Both niacin (nicotinic acid) and fibrates are recommended as options for combination with a statin in this setting. Data from ongoing prospective outcomes studies are needed to evaluate the efficacy and safety of these combinations...
  31. ncbi request reprint Novel nonstatin strategies to lower low-density lipoprotein cholesterol
    Michael H Davidson
    Radiant Research, 515 North State Street, Suite 2700, Chicago, IL 60654, USA
    Curr Atheroscler Rep 11:67-70. 2009
    ..Although each of these novel therapies effectively lowers LDL-C, challenges remain in the clinical development to assess long-term safety...
  32. ncbi request reprint Atherosclerosis surrogate imaging trials come of age: for better or for worse?
    Michael H Davidson
    Radiant Research, 515 North State Street, Suite 2700, Chicago, IL 60654, USA
    Curr Cardiol Rep 10:521-5. 2008
    ..In light of the cost and time involved to complete morbidity trials demonstrating the benefit of potential antiatherosclerotic agents, surrogate imaging trials are necessary to expedite the regulatory approval process...
  33. ncbi request reprint Retrospective comparison of the effectiveness of a fenofibrate 145 mg formulation compared with the standard 160 mg tablet
    Michael H Davidson
    University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
    Clin Drug Investig 28:615-23. 2008
    ....
  34. ncbi request reprint Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications
    Michael H Davidson
    University of Chicago Pritzker School of Medicine, Chicago, IL 60610, USA
    Cleve Clin J Med 75:479-82, 486-8, 490-1. 2008
  35. doi request reprint Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines
    Michael H Davidson
    Preventive Cardiology Center, Pritzker School of Medicine, University of Chicago, 515 North State Street, Chicago, IL 60610, USA
    Am J Cardiol 101:51F-57F. 2008
    ..However, at this time Lp-PLA(2) cannot be recommended as a target of therapy...
  36. ncbi request reprint Statin safety: an appraisal from the adverse event reporting system
    Michael H Davidson
    Rush University Medical Center, Chicago, Illinois, USA
    Am J Cardiol 97:32C-43C. 2006
    ..Postrosuvastatin AE reporting patterns were comparable to those seen with other statins and did not resemble cerivastatin...
  37. ncbi request reprint Striated muscle safety of ezetimibe/simvastatin (Vytorin)
    Michael H Davidson
    Rush University Medical Center, Chicago, Illinois, USA
    Am J Cardiol 97:223-8. 2006
    ..Thus, the clinical trial experience with ezetimibe/simvastatin suggests that ezetimibe does not enhance or aggravate the muscle effects of simvastatin...
  38. ncbi request reprint A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d
    Michael H Davidson
    Radiant Research Chicago, Chicago, Illinois 60610, USA
    Clin Ther 25:2738-53. 2003
    ..The available statin drugs have similar pharmacodynamic properties but are not equal in low-density lipoprotein cholesterol (LDL-C)-lowering efficacy...
  39. doi request reprint Hypercholesterolemia treatment patterns and low-density lipoprotein cholesterol monitoring in patients with a diagnosis of atherosclerosis in clinical practice
    Michael H Davidson
    Pritzker School of Medicine, University of Chicago, Chicago, Illinois 60610, USA
    Am J Med 122:S51-9. 2009
    ..The results from this study, which was conducted in a routine clinical practice setting, indicate the opportunities and the need for better monitoring and management of lipid levels in patients with atherosclerosis...
  40. ncbi request reprint Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events
    Michael H Davidson
    Department of Preventive Cardiology, Rush Presbyterian St Luke s Medical Center, 1725 West Harrison Street, Chicago, IL 60612, USA
    Curr Atheroscler Rep 5:418-22. 2003
  41. ncbi request reprint Newer pharmaceutical agents to treat lipid disorders
    Michael H Davidson
    Rush Presbyterian St Luke s Medical Center, 1725 West Harrison Street, Suite 1159, Chicago, IL 60612, USA
    Curr Cardiol Rep 5:463-9. 2003
    ....
  42. ncbi request reprint Biologic therapies for dyslipidemia
    Michael H Davidson
    Department of Preventive Cardiology, Rush University Medical Center, 1725 West Harrison Street, Suite 1159, Chicago, IL 60612, USA
    Curr Atheroscler Rep 6:69-72. 2004
    ..Gene therapies to reduce low-density lipoproteins and increase high-density lipoproteins are on the horizon, but the ability to safely prolong gene expression in humans will require the development of novel vectors...
  43. ncbi request reprint Combination therapy in the management of complex dyslipidemias
    Michael H Davidson
    Rush Medical College, Rush University Medical Center, Chicago, Illinois, USA
    Curr Opin Lipidol 15:423-31. 2004
    ..This review discusses the need for comprehensive management of all abnormalities in a given patient's lipoprotein profile and for the use of combinations of anti-lipidemic medications, when indicated...
  44. ncbi request reprint Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia
    M H Davidson
    Radiant Research, Chicago, IL 60610 4324, USA
    Int J Clin Pract 58:746-55. 2004
    ..Ezetimibe + statin had a safety profile similar to statin monotherapy. Coadministration of ezetimibe + statin offers a well-tolerated, highly efficacious new treatment strategy for patients with hypercholesterolemia...
  45. ncbi request reprint Rosuvastatin safety: lessons from the FDA review and post-approval surveillance
    Michael H Davidson
    Rush Medical College, Rush University Medical Center, Chicago, Illinois, USA
    Expert Opin Drug Saf 3:547-57. 2004
    ..In the post-marketing surveillance for rosuvastatin, there have been reports of rhabdomyolysis, but the incidence rate, when corrected for prescription utilisation, is similar to other statins following initial approval...
  46. ncbi request reprint Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations
    Michael H Davidson
    Radiant Development, Chicago, Illinois, USA
    Am J Cardiol 96:556-63. 2005
    ..Most of those (75%) with cardiovascular disease in NEPTUNE II would be considered very high risk and candidates for aggressive therapy to reach the new optional treatment goals...
  47. ncbi request reprint Comparative effects of lipid-lowering therapies
    Michael H Davidson
    Radiant Research, Rush Medical College, Rush University Medical Center, Chicago, IL 60602, USA
    Prog Cardiovasc Dis 47:73-104. 2004
    ..This trend portends an ever-growing need for the aggressive and judicious use of different antilipidemic medication(s) in patients at risk for all forms of atherosclerotic vascular disease...
  48. ncbi request reprint Management of dyslipidemia in patients with complicated metabolic syndrome
    Michael H Davidson
    Division of Preventive Cardiology, Department of Medicine, Rush University Medical Center, Chicago, Illinois 60612, USA
    Am J Cardiol 96:22E-25E. 2005
    ..HIV lipodystrophy is associated with a marked risk of coronary artery disease (CAD), and more aggressive management of the dyslipidemia is likely necessary to improve the prognosis...
  49. ncbi request reprint Reducing residual risk for patients on statin therapy: the potential role of combination therapy
    Michael H Davidson
    Rush Medical College, Rush University Medical Center, Chicago, Illinois 60610, USA
    Am J Cardiol 96:3K-13K; discussion 34K-35K. 2005
    ..This article discusses the role of combination therapy in managing CAD and in achieving optional targets in high-risk patient populations...
  50. ncbi request reprint Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions
    Michael H Davidson
    Rush University, Preventive Cardiology Center, Rush Presbyterian St Luke s Medical Center, 515 State Street, Suite 2700, Chicago, IL, USA
    Expert Opin Drug Saf 5:145-56. 2006
    ..The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study in 10,000 patients with Type 2 diabetes mellitus is testing the efficacy and safety of fenofibrate/statin combination...
  51. ncbi request reprint Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study
    Michael H Davidson
    Radiant Research Inc, Chicago, IL 60610, USA
    Clin Ther 27:715-27. 2005
    ..There is a need for new formulations that have improved bioavailability and eliminate the requirement for administration with food...
  52. ncbi request reprint Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation
    Michael Davidson
    Department of Preventive Cardiology, Rush University Medical Center, 1725 West Harrison Street, Chicago, IL 60612, USA
    Prev Cardiol 8:244-9. 2005
    ..Lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, and rosuvastatin are the available statins in the United States...
  53. ncbi request reprint Lipid responses to plant-sterol-enriched reduced-fat spreads incorporated into a National Cholesterol Education Program Step I diet
    K C Maki
    Chicago Center for Clinical Research, IL 60610, USA
    Am J Clin Nutr 74:33-43. 2001
    ..Plant sterol esters reduce cholesterol absorption and lower circulating blood cholesterol concentrations when incorporated into the habitual diet...
  54. ncbi request reprint Statin trials in progress: unanswered questions
    M H Davidson
    Chicago Center for Clinical Research, Rush Presbyterian-St. Luke's, 515 North State Street, Suite 2700, Chicago, IL 60610, USA
    Curr Atheroscler Rep 3:9-13. 2001
    ....
  55. ncbi request reprint Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia
    M H Davidson
    The Chicago Center for Clinical Research, Chicago, Illinois, USA
    Clin Cardiol 24:467-74. 2001
    ..CONCLUSIONS: Combination colesevelam and lovastatin was efficacious and well tolerated, resulting in additive decreases in LDL cholesterol levels whether or not both agents were administered simultaneously...
  56. ncbi request reprint Long-term effects of consuming foods containing psyllium seed husk on serum lipids in subjects with hypercholesterolemia
    M H Davidson
    Chicago Center for Clinical Research, IL 60610, USA
    Am J Clin Nutr 67:367-76. 1998
    ..Although modest, the effect of 10.2 g PSH/d on LDL cholesterol (relative to the control) persisted throughout the 24-wk treatment period, indicating potential for long-term benefit...
  57. ncbi request reprint Comparison of the effects of lean red meat vs lean white meat on serum lipid levels among free-living persons with hypercholesterolemia: a long-term, randomized clinical trial
    M H Davidson
    Chicago Center for Clinical Research, IL 60610, USA
    Arch Intern Med 159:1331-8. 1999
    ....
  58. ncbi request reprint Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust
    M H Davidson
    Chicago Center for Clinical Research, Illinois 60610, USA
    Drugs 61:197-206. 2001
    ..Thus, it can be concluded that HMG-CoA reductase inhibitors are well tolerated, effective treatments for hypercholesterolaemia...
  59. ncbi request reprint Safety and tolerability of esterified phytosterols administered in reduced-fat spread and salad dressing to healthy adult men and women
    M H Davidson
    Chicago Center for Clinical Research, Illinois 60610, USA
    J Am Coll Nutr 20:307-19. 2001
    ..0 g/day arm (-13.3%, p < 0.05). DISCUSSION: The results of this study indicate that phytosterol esters are well tolerated and show no evidence of adverse effects at a daily intake of up to 9.0 g of phytosterols for eight weeks...
  60. ncbi request reprint Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent
    M H Davidson
    Nutrition and Metabolism Research Unit, Chicago Center for Clinical Research, 515 North State Street, Suite 2700, Chicago, IL 60610, USA
    Expert Opin Investig Drugs 9:2663-71. 2000
    ..Colesevelam, recently approved by the US FDA, represents a valuable non-absorbed alternative in the armamentarium against hypercholesterolaemia, both for monotherapy and combination therapy, as an adjunct to diet and exercise...
  61. ncbi request reprint Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia
    Michael Davidson
    Chicago Center for Clinical Research, Chicago, Illinois, USA
    Am J Cardiol 89:268-75. 2002
    ..Both treatments were well tolerated...
  62. ncbi request reprint Treatment of the elderly with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: focus on drug interactions
    M H Davidson
    Chicago Center for Clinical Research, 515 North State Street, Chicago, IL 60610, USA
    J Cardiovasc Pharmacol Ther 6:219-29. 2001
    ..The elderly population, while at high risk for CVD, is currently undertreated. Statins can effectively lower low-density lipoprotein cholesterol levels and lessen the risk of CVD for this population...
  63. doi request reprint Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation
    John D Brunzell
    Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, Northwest Lipid Laboratory, University of Washington, Seattle, Washington, USA
    J Am Coll Cardiol 51:1512-24. 2008
  64. ncbi request reprint Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia
    Jonathan Isaacsohn
    Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, USA
    Clin Cardiol 26:18-24. 2003
    ....
  65. ncbi request reprint Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia
    Michael H Davidson
    Chicago Center for Clinical Research, Illinois 60610, USA
    J Am Coll Cardiol 40:2125-34. 2002
    ..The purpose of this study was to assess the efficacy and safety of ezetimibe administered with simvastatin in patients with primary hypercholesterolemia...
  66. ncbi request reprint Is LDL-C passed its prime? The emerging role of non-HDL, LDL-P, and ApoB in CHD risk assessment
    Michael H Davidson
    Arterioscler Thromb Vasc Biol 28:1582-3. 2008
  67. ncbi request reprint Statin safety: an assessment using an administrative claims database
    Mark J Cziraky
    HealthCore, Inc, Wilmington, Delaware 19801, USA
    Am J Cardiol 97:61C-68C. 2006
    ..No hospitalized cases of the index AEs were observed in study subjects during the 6-month period before initiation of the lipid-lowering drug. Statin monotherapy as currently prescribed is generally well tolerated and safe...
  68. ncbi request reprint Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study
    Richard H Karas
    Division of Cardiology, Molecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts, USA
    Am J Cardiovasc Drugs 8:69-81. 2008
    ..This fact has focused increased attention on treating abnormalities of non-high-density lipoprotein-cholesterol (non-HDL-C), HDL-C, and triglycerides in national guidelines and has intensified interest in combination therapy...
  69. ncbi request reprint Management of hypercholesterolaemia in postmenopausal women
    Michael H Davidson
    Chicago Center for Clinical Research, Illinois 60610, USA
    Drugs Aging 19:169-78. 2002
    ..The effects of each type of therapy and potential adverse effects should also be considered...
  70. ncbi request reprint Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial
    Theodore Mazzone
    Department of Medicine, Section of Endocrinology, Diabetes and Metabolism, University of Illinois College of Medicine, Chicago 60612, USA
    JAMA 296:2572-81. 2006
    ..While studies of relatively short duration have suggested that thiazolidinediones such as pioglitazone might reduce progression of CIMT in persons with diabetes, the results of longer studies have been less clear...
  71. ncbi request reprint Risk for myopathy with statin therapy in high-risk patients
    Christie M Ballantyne
    Center for Cardiovascular Disease Prevention, Baylor College of Medicine, 6565 Fannin, Mail Station A601, Suite A656, Houston, TX 77030, USA
    Arch Intern Med 163:553-64. 2003
    ..Clinicians should be alert to the potential for drug-drug interactions to minimize the risk of myopathy during long-term statin therapy in patients at high risk for coronary heart disease...
  72. ncbi request reprint Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin
    Daniel J Rader
    University of Pennsylvania School of Medicine, Philadelphia 19104, USA
    Am J Cardiol 91:20C-23C; discussion 23C-24C. 2003
    ..001). Mean percent reductions from baseline in the LDL cholesterol/HDL cholesterol ratio were 52%, 39%, and 30% for rosuvastatin 10 mg, simvastatin 20 mg, and pravastatin 20 mg, respectively, in these 2 trials...
  73. ncbi request reprint Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin
    James M McKenney
    National Clinical Research Inc, 2809 Emerywood Parkway, Ste 140, Richmond, VA 23294, USA
    J Cardiovasc Pharmacol 46:594-9. 2005
    ..Selecting the starting dose of atorvastatin using a treatment algorithm achieves NCEP ATP III LDL-cholesterol goals in the majority of patients and minimizes the need for dose titration...
  74. ncbi request reprint Application of recent definitions of the metabolic syndrome to survey data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE II)
    Prakash C Deedwania
    University of California San Francisco, School of Medicine, Fresno, CA 93703, USA
    J Cardiometab Syndr 1:295-300. 2006
    ..The metabolic syndrome is common in patients receiving lipid-lowering therapy in an office-based setting. Three recent definitions resulted in similar estimates of its prevalence...
  75. ncbi request reprint Emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome
    Michael H Davidson
    Radiant Research, Chicago, Illinois, USA
    Am J Cardiol 93:3C-11C. 2004
    ..This article reviews emerging therapeutic strategies for the management of dyslipidemia in patients with the MS...
  76. ncbi request reprint Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients
    Alberico L Catapano
    University of Milan, Milan, Italy
    Curr Med Res Opin 22:2041-53. 2006
    ..To assess the lipid-altering efficacy and safety of ezetimibe/simvastatin single tablet product compared with rosuvastatin at the approved usual starting, next highest, and maximum doses...
  77. ncbi request reprint Combination therapy for dyslipidemia: safety and regulatory considerations
    Michael H Davidson
    Chicago Center for Clinical Research, Rush Medical College, Chicago, Illinois 60612, USA
    Am J Cardiol 90:50K-60K. 2002
    ..This article discusses several safety and regulatory considerations for the use of combination therapy for dyslipidemia...
  78. ncbi request reprint Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction
    Jennifer G Robinson
    University of Iowa, Lipid Research Clinic, Departments of Epidemiology and Medicine, 200 Hawkins Drive, SE 226 GH, Iowa City, IA 52242, USA
    Expert Rev Cardiovasc Ther 4:461-76. 2006
    ..Ezetimibe 10 mg/simvastatin 80 mg lowers LDL by approximately 60% and has been demonstrated to be superior to the highest doses of atorvastatin and rosuvastatin for lowering LDL and raising high-density lipoprotein...
  79. ncbi request reprint Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS)
    Christie M Ballantyne
    Baylor College of Medicine, Houston, Tex 77030, USA
    Am Heart J 146:862-9. 2003
    ..Previous studies have shown that effects on high-density lipoprotein cholesterol (HDL-C) may differ among statins...
  80. ncbi request reprint Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting
    Kathleen M Fox
    Am J Manag Care 13:S270-5. 2007
    ..The study compared low-density lipoprotein cholesterol (LDL-C) reduction obtained after switching patients on a statin therapy to rosuvastatin or simvastatin in real-world clinical practice...
  81. ncbi request reprint Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database
    Kathleen M Fox
    Department of Epidemiology and Preventive Medicine, School of Medicine, University of Maryland, Baltimore, MD, USA
    Clin Ther 29:2385-94. 2007
    ..Lipid management in clinical practice has been suboptimal with a significant proportion of patients not achieving recommended cholesterol levels. A reason for low goal attainment may be the limited use of upward dose titration...
  82. doi request reprint Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, 3288 Illinois Avenue, Louisville, KY 40213, USA
    Expert Rev Cardiovasc Ther 6:391-409. 2008
    ....
  83. ncbi request reprint Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force
    James M McKenney
    National Clinical Research, Virginia Commonwealth University, Richmond, Virginia 23294, USA
    Am J Cardiol 97:89C-94C. 2006
    ..Practical guidance in the form of recommendations to health professionals who manage the coronary artery disease risk of patients with statin therapy is provided...
  84. doi request reprint Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy
    Tamar S Polonsky
    University of Chicago, Pritzker School of Medicine, Chicago, Illinois 60637 1470, USA
    Am J Cardiol 101:27B-35B. 2008
    ..In this article, the authors review the use of combination therapy as a strategy for risk reduction in CAD...
  85. ncbi request reprint Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)
    Peter H Jones
    Baylor College of Medicine, 6565 Fannin Avenue, A 601, Houston, TX 77030, USA
    Am J Cardiol 92:152-60. 2003
    ..0 mmol/L was achieved by 79% to 92% in rosuvastatin groups compared with 52% to 81% in atorvastatin groups. Drug tolerability was similar across treatments...
  86. doi request reprint The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-bl
    Emile R Mohler
    University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    J Am Coll Cardiol 51:1632-41. 2008
    ..This study examined the effects of darapladib, a selective lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) inhibitor, on biomarkers of cardiovascular (CV) risk...
  87. ncbi request reprint Effects of high-fiber oat and wheat cereals on postprandial glucose and lipid responses in healthy men
    Kevin C Maki
    Radiant Research, Chicago, IL, USA
    Int J Vitam Nutr Res 77:347-56. 2007
    ..64 +/- 0.91 vs. 3.38 +/- 0.98 hours x mmol/L, p = 0.018). These results suggest that high-fiber oat cereal influenced postprandial triglyceride and free fatty acid levels, which may have implications regarding cardiovascular disease risk...
  88. ncbi request reprint Combination lipid-lowering therapy in diabetes
    Michael H Davidson
    Chicago Center for Clinical Research, Rush Presbyterian St Luke s Medical Center, 1725 West Harrison Street, Suite 1159, Chicago, IL 60612, USA
    Curr Diab Rep 3:263-8. 2003
    ..For diabetic patients who require additional LDL lowering, ezetimibe may provide a safe combination to a statin to achieve the LDL goal of less than 100 mg/dL...
  89. ncbi request reprint Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin
    Peter H Jones
    Baylor College of Medicine, Houston, Texas 77030, USA
    Am J Cardiol 95:120-2. 2005
    ..The findings suggest that the use of fenofibrate in combination with statins results in fewer reports of rhabdomyolysis per million prescriptions dispensed than does the use of gemfibrozil...